PPT-Selecting Direct Oral Anticoagulants and Reversal Agents

Geno J Merli MD MACP FSVM FHM Professor Medicine amp Surgery Sidney Kimmel Medical College Thomas Jefferson University Hospitals Disclosures Geno J Merli MD Research Grant BMSPfizer ADIOS study completed 122019 Presented ACC Meeting 32019. Reversal of Anticoagulants at UCDMC Introduction Bleeding complications are a common concern with the use of anticoagulant agents In selected situations reversing or neutralizing the effects of an anticoagulant may be desired Table 1 Considerations Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . . What Do the Data Suggest? . Testing for NOAC Levels. re-verse . AD . Reversal Agents. Reversal Agents in Clinical Practice. BRIDGE Study. Managing Bleeding Complications. Reversal Agents. Abbreviations. We Now?. Moderator. Christian T. Ruff, MD, MPH. Assistant Professor of Medicine. TIMI Study Group. Brigham and . Women's . Hospital. Harvard Medical School. Boston, Massachusetts. Arash Afshinnik, MD. Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. and major trauma. Dr. Tina . Biss. Consultant . Haematologist. Newcastle Hospitals NHS Foundation Trust. NTN Annual Trauma . Conference. 17. th. April 2015. Case history. 73 year old female . Anticoagulated. , . BCPS, BCCCP. Associate Professor | Department of Pharmacy Practice. Anticoag. : Update on Pipeline Agents for TSOAC . Reversal. Conflict of Interest. I have no actual or potential conflicts of interest in relation to this program to disclose.. Introduction/Overview . VKA-Associated Bleeding: . Results From the RADOA Registry . Reversal Agents for VKA-Associated Anticoagulation. Management of Urgent Anticoagulation Reversal: . 4F-PCC vs FFP. Nathan Culver, . PharmD. , BCPS. anticoagulant Medication Classes. Direct Thrombin Inhibitors (DTI). Argatroban. Bivalrudin. Dabigatran (Pradaxa®). Betrixaban (. Bevyxxa. ®). Factor . Xa. Inhibitors. Assistant Professor. Department of Internal Medicine – Hospital Medicine Division. Medical Director – UNM Anticoagulation Clinic. Co-Director Antithrombotic Stewardship. Roadmap. Direct oral anticoagulants. April 2020 NAMES ELIMINATION HALF - LIFE REMOVED BY HD STRATEGIES TO REVERSE OR MINIMIZE DRUG EFFECT apixaban (Eliquis) 8 - 15 hours (longer in renal impairment) NO  Drug activity can be assessed This presentation is based on the . December 2013. AHRQ WebM&M Spotlight Case. See the full article at . http://webmm.ahrq.gov. . CME credit is available. Commentary by: . Margaret . C. Fang. , MD, MPH, University of California, San Francisco. By:. . Akash Saxena. KLE . College of Pharmacy, . Belagavi. A constituent Unit of KLE Academy of Higher Education and Research. Nehru Nagar, . Belagavi. . –. 590 010, Karnataka, India. Phone:. 0831-2471399;.